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Many men and women deal with fertility whether it’s needing infertility treatments or 
contraceptives. The follicle stimulating hormone (FSH) and follicle stimulating hormone 
receptor (FSHR) play important roles in reproduction and fertility in both males and females. 
Fertility issues can arise when interactions between FSH and FSHR aren’t functioning properly 
and FSHR signaling is disrupted. FSHR is a G-protein coupled receptor (GPCR) found on the 
cell surface of granulosa cells in women and Sertoli cells in men. Activated FSHR initiates a 
cascade of downstream signaling events that result in different biological effects such as ovarian 
follicular development and estrogen production in women and sperm production and regulation 
in men. To create better birth control and fertility treatment options, FSHR signaling is a 
desirable target. Understanding how the receptor functions can offer insights for how it can be 
manipulated. Therefore, the effector proteins involved in FSHR signaling must be identified and 
understood. The APEX Assay has been developed to study these interactions for different 
GPCRs. This assay uses an engineered ascorbate peroxidase attached to the carboxyl terminus of 
FSHR which tags proteins within a small radius. Using mass spectrometry, the biotinylated 
proteins can be quantitatively analyzed to give a better understanding of the proteins associated 
with FSHR. HEK293 cells are currently being utilized to create a stable cell line expressing the 
FSHR-APEX receptor. The FSHR-APEX receptor can then be used in the APEX Assay to 
analyze proteins involved in FSHR signaling, allowing for the creation of  birth control methods 
and fertility treatments that target the FSHR signaling pathways.  
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Fertility is a necessary part of life that allows species to reproduce. However, many men 
and women suffer from infertility and thus require additional methods to increase chances of 
pregnancy. Infertility is usually defined as the inability to conceive after one year of unprotected 
sex (Infertility). Approximately 9% of men and 11% of women of reproductive age experience 
issues with fertility (How common). The current methods for treatment can include drugs to 
stimulate ovulation, intrauterine insemination (IUI), and in vitro fertilization (IVF) (​Farley, 
2007). The cost of fertility treatments, ranging from about $2,000 for medication to about 
$24,000 for IVF (Advanced Fertility), poses a problem for many individuals seeking treatment 
for infertility. Thus, there is a need for an effective, low cost option for those who cannot afford 
IVF or other costly methods. However, ​there are many possible reasons that cause one to be 
infertile, bringing forth a challenge when considering new possible treatments. Therefore, 
understanding the biological pathways and mechanisms that contribute to fertility is important 
for drug development and other potential treatment options.  
 One possible mechanism causing infertility in both men and women involves the Follicle 
Stimulating Hormone (FSH). The human Follicle Stimulating Hormone (hFSH) is a 
gonadotropin which plays an important role in proper maturation and maintenance of the 
reproductive systems and is part of the hypothalamic pituitary gonadal axis (Figure 1). The 
hypothalamus releases gonadotropin releasing hormone (GnRH) which stimulates the anterior 
pituitary. Under hypothalamic control, the anterior pituitary gland secretes FSH, along with other 
hormones like luteinizing hormone (LH), which travel to target areas within the body and bind to 
specific receptors (Rawindraraj, 2019). After secretion, FSH binds to the FSH Receptor (FSHR) 
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to initiate a response. Upon ligand binding of FSH to FSHR, a biological response occurs in both 
the ovaries and the testes. In females, the maturation of ovarian follicles and estrogen production 
occurs and in males, sperm production is initiated and regulated (Lui et al, 2017; Ramaswamy et 
al, 2014). More specifically, in females, after stimulation by FSH, the ovarian follicle grows and 
differentiates into preovulatory follicles. Follicles that are FSH responsive are selected to 
continue maturation. Follicles that either don’t respond or have a low level response to FSH 
undergo atresia. Upon maturation, follicles are continually selected for until the strongest one is 
released during ovulation. ​In males, FSH is necessary for Sertoli cell proliferation and to 
maintain normal spermatogenesis ​(​Ulloa-Aguirre et al, 2008). It is clear that without FSH and its 





On the other side of this story there is the need for better contraceptive methods. Since 
FSH and its receptor play such a large role in human fertility, it’s a desired target for birth 
control drugs. Current birth control methods for females include but aren’t limited to birth 
control pills and intrauterine devices (IUD). Both are decently effective methods, however, the 
pill must be taken at the same time everyday to maximize efficiency and the IUD is a foreign 
object that must be placed inside the body. The average yearly cost is up to $800 for birth control 
pills and up to $1,300 for an IUD depending on health care coverage (The cost of Birth). Despite 
being expensive, birth control methods can also interrupt the normal levels of estrogen and 
progesterone in females. Targeting the FSHR signaling pathway is an attractive target for 
alternative contraceptive methods because it has the potential to offer effective birth control 
options while limiting hormonal side effects, thus not only providing an affordable alternative, 
but also providing an alternative that does not disrupt the normal hormone levels in females. It 
also gives hope to one day create birth control methods for males since FSH is involved in male 
reproductivity as well.  
The FSHR is part of the G-protein coupled receptor (GPCR) family, and therefore has a 
variety of signaling pathways and mechanisms that can have different biological effects. GPCRs 
have an extracellular domain (N-terminus), an intracellular domain (C-terminus), and a 
transmembrane domain consisting of seven 𝛼-helices looping back and forth across the cell 
membrane (Figure 2). The extracellular domain is where ligand binding and consequently 
activation of the receptor occurs. The intracellular domain is the part of the receptor that interacts 





FSH is a heterodimer consisting of an 𝛼-subunit and a 𝛽-subunit (​Ulloa-Aguirre et al, 
2008)​ which binds to the extracellular domain of the FSHR initiating a cascade of downstream 
signaling, leading to a variety of biological effects. The network of signaling is complicated with 
many intertwining pathways. The most researched and understood pathway is through the 
activation of the G𝛼s subunit of the heterotrimeric G-protein. Other pathways include signaling 




The most understood pathway for FSHR signaling is through the activation of 
heterotrimeric G-proteins. Upon ligand binding, FSHR undergoes a conformational change 
which then activates the G-protein by catalyzing the exchange from GDP to GTP on the G𝛼 
subunit (Figure 4). The G-protein then dissociates into its now active G𝛼 and G𝛽/𝛾 subunits, both 
of which subsequently activate other downstream effector proteins. Desensitization occurs when 
𝛽-arrestin binds to FSHR to halt signal transduction and GTPase hydrolyzes GTP to GDP, 
rendering the G𝛼 subunit inactive, which then re-associates with the G𝛽/𝛾 dimer to form the 




The most understood G𝛼 subunit is the G𝛼s subunit. When activated, it induces adenylyl 
cyclase which mediates the production of cyclic adenosine monophosphate (cAMP). As the 
accumulation of cAMP in the cell increases, it binds to and activates two downstream effectors 
(Gloaguen et al, 2011). These downstream effectors are Protein Kinase A (PKA) and exchange 
proteins activated by cAMP (EPAC). When PKA is activated, active catalytic subunits are 
released and able to phosphorylate many targets in the cytosol or nucleus (Gloaguen et al, 2011). 
Other downstream proteins such as p38 MAPK and ERK1/2 (p44/42 MAP kinase) are activated 
by PKA (​Ulloa-Aguirre et al, 2016) which initiates and maintains transcription factors that can 
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have different biological effects such as cell growth and proliferation. ​EPAC on the other hand, 
promotes Rap1-GDP to GTP and thus activation in granulosa and epithelium ovary cells 
(Gloaguen et al, 2011). The activation of Akt, p38 MAPK and ERK1/2 are dependent upon 
successful activation of Rap1 by EPAC. Both effector proteins, PKA and EPAC, are activated by 
cAMP but have different signaling pathways, yet the downstream effects have some overlap 
(Figure 5). While there are other pathways involving different G𝛼 subunits, the G𝛼s is the main 





The 𝛽-arrestin pathway is known for its desensitization and recycling of FSHR signaling. 
However, recent findings suggest that 𝛽-arrestins may play a more general role (Figure 6). These 
𝛽-arrestins are seen as adapters and transducers which lead to the activation of MAPK and ERK 
(​Gloaguen et al, 2011).​ ​Desensitization of FSHR signaling occurs in a two step mechanism 
where GPCR kinases (GRKs) phosphorylate FSHR and ​𝛽-arrestin binds to the intracellular 
domain of the receptor, physically blocking and uncoupling the G-protein from the receptor 
(​Jean-Charles et al, 2017). ​𝛽-arrestins also recruit nucleotide phosphodiesterases (PDEs) and 
diacylglycerol kinases (DGKs) which work to degrade secondary messengers that are 
downstream of the activated receptor, including the conversion of cAMP to AMP (​Jean-Charles 
et al, 2017). The decreasing levels of cAMP will thus result in decreased PKA and EPAC 
activity, resulting in the signaling through the G​𝛼s/cAMP/PKA/EPAC pathway to diminish. 
With the translocation of 𝛽-arrestin to the activated receptor and the recruitment of DGKs, the 
diacylglycerol (DAG) is phosphorylated and then converted into phosphatidic acid (​Jean-Charles 
et al, 2017). Phosphatidic acid has been found to be involved in many different cellular 
processes. These processes include cell proliferation, secretion, cytoskeletal organization, cell 
survival, and vesicular trafficking (Liu et al, 1970). This indicates that even though ​𝛽-arrestins 
are involved with FSHR desensitization, they also can initiate separate G-protein-independent 
signaling mechanisms through the production of phosphatidic acid.  
There are other signaling pathways involving FSHR. Some of these include different G𝛼 
subunits such as G𝛼i and G𝛼q. However, the main pathways that will be focused on are the 
G𝛼s/cAMP/PKA/EPAC mechanism and the 𝛽-arrestin mechanism. These are the most 




The objective of this research is to identify proteins involved in FSHR signaling and to 
gain a better understanding of how FSHR signals. Understanding the signaling pathways that 
FSH and its receptor are involved in is a critical step. The information can be used for identifying 
potential drug targets to treat infertility and to provide alternative methods for contraceptives.  
The APEX Assay is a relatively new technique that has been used in other recent research 
to understand the different interactions between GPCR’s and effector proteins. APEX is a 
genetically engineered ascorbate peroxidase. When the substrate biotin-phenol is added along 
with hydrogen peroxide, APEX creates a biotin-phenoxy radical (Paek et al, 2017) by stripping a 
hydride​ ​from biotin phenol. Since radicals are short-lived and very reactive, the biotin-phenoxy 
radicals interact with proteins. However, because these radicals are so short-lived, they only 
interact with proteins within a small radius from the APEX protein, thus tagging these proteins. 
The biotinylated proteins can be isolated and analyzed using mass spectrometry (Figure 7). By 
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developing a modified GPCR where the APEX protein is attached to the carboxy terminus, 
proteins tagged within a small proximity of the APEX protein are ultimately within a small 
proximity of the GPCR. This enables researchers to better identify the different proteins and 
understand the protein-protein interactions that occur during GPCR signaling. By creating a 
modified FSHR-APEX plasmid encoding for FSHR with APEX attached to the carboxy 















Creation of FSHR-APEX Plasmid: 
Stage 1 PCR was performed to amplify both the pCN42𝛥B template and the APEX 
template. The pCN42𝛥B plasmid was amplified using the primer FSHR-Bam and the primer #2​. 
The APEX plasmid was also amplified using the primer APEX-Not and the primer #3. Stage 2 
PCR was performed to connect the FSHR and the APEX DNA products using the FSHR-Bam 




The DNA product was purified with a mini column. Two restriction digests were 
performed with restriction enzymes Not1 and BamHI to cut both the FSHR-APEX DNA product 
from the stage 2 PCR and the pCN42𝛥B plasmid. Gel electrophoresis was performed and the 
restriction digest products were gel purified to isolate the FSHR-APEX template and the 
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pCN42𝛥B vector. The FSHR-APEX template and pCN42𝛥B vector were ligated together in a 
20uL reaction with 10X buffer, water, and ligase and was incubated at room temperature for one 
hour. Next, competent cells were transformed with the new FSHR-APEX plasmid and shaken in 
SOC Outgrowth Medium for one hour at 37°C and subsequently plated on LB plates with 
ampicillin and incubated overnight. Colonies were selected and grown overnight in LB medium 
supplemented with ampicillin. Cells were lysed and the DNA was isolated using a mini column. 
Two separate restriction digests were performed: the first using restriction enzyme EcoR5 and 
the second using restriction enzyme BamHI. A third restriction digest was performed to confirm 
the results using restriction enzymes BamHI and Not1. Cultures containing the FSHR-APEX 
plasmid were grown overnight in LB medium supplemented with ampicillin and DNA was 
isolated and extracted and stored at 4°C. The extracted DNA concentration was determined using 
the NanoDrop technology. 
  
Stable Transfection of FSHR-APEX Plasmid: 
HEK293 cells were grown to approximately 60% confluency in a 60mm dish. The cells 
were then transfected with the FSHR-APEX plasmid using TransIT 293 and following the 
transfection protocol from the ​Team Cohen Master Lab Manual​. After approximately a 72 hour 
incubation period, the media was supplemented with G418. The G418 media was changed every 
48 hours until cells that did not take up the plasmid were killed off. Once individual colonies 
were seen, the media was removed and the cells were washed once with sterile PBS. The 
colonies were lifted with a trypsinized disc and moved to a 24-well dish. Clones were transferred 
to a larger dish depending on the rate of growth. 
 
13 
 FSH Treatment of Transient FSHR-APEX Plasmid Transfection: 
HEK293 cells were grown to approximately 60% confluency in a 6-well dish. The cells 
were transfected with the FSHR-APEX plasmid using TransIT 293. After a 48-72 hour 
incubation period, cells were treated with FSH in a time course fashion. Cells were then 
harvested, lysed, and analyzed by western blotting. 
  
Western Blot Analysis: 
A 10% SDS-PAGE gel was made following the protocol in the ​Team Cohen Master Lab 
Manual​. Cells were harvested and lysed from a 6-well dish and SDS-PAGE gel electrophoresis 
was performed. The gels were transferred to an Immobilon-P membrane following the Bio-Rad 
Semi Dry Transfer protocol in the ​Team Cohen Master Lab Manual​. Membranes were incubated 
in 5% milk in TBST. Primary antibody used was the anti-hFHSR monoclonal antibody 106.105 
(kind gift of Dr. James Dias, University of Albany) and the secondary antibody used was 
goat-anti-mouse HRP. 
  
Fluorescent Microscopy Analysis: 
Cells were plated on a poly-lysine coated coverslip in a 6-well dish and grown until 
confluent. The protocol for fluorescent microscopy was followed from the ​Team Cohen Master 
Lab Manual​. Coverslips were incubated in 5% BSA in PBS. Primary antibody used was 
anti-hFHSR monoclonal antibody 106.105 and the secondary antibody used was green 





Stage 1 PCR was performed on the pCN42𝛥B template and the APEX template. Each 
template was amplified in separate PCR reactions. Gel electrophoresis was performed to confirm 
that each template was correct (Figure 8). The blue arrow in Figure 8 indicate the APEX 





Stage 2 PCR was performed to connect the amplified APEX stage 1 product to the 
pCN42𝛥B stage 1 amplified product (containing the hFSHR gene). Gel electrophoresis was 




The FSHR-APEX DNA product from the stage 2 PCR seen by the yellow arrow in 
Figure 10 and the pCN42𝛥B expression vector seen by the blue arrow in Figure 10 were run on 
an agarose gel and subsequently gel purified. This was done to isolate the FSHR-APEX template 






Once the FSHR-APEX DNA product and the pCN42𝛥B expression vector were isolated 
and purified from the gel, they were ligated together to create a new plasmid containing the 
FSHR-APEX template. Competent cells were transformed, grown, and plated, and 12 colonies 
were selected. These colonies were grown in an overnight culture and the DNA was isolated and 
analyzed to determine if the ligation was successful. Restriction digests were performed to look 
for different products when compared to the wild-type pCN42𝛥B template seen in lane 2 of 
Figure 11 and Figure 12. The first restriction digest used the enzyme EcoR5. Two colonies 
produced different products when compared to the wild-type FSHR template as indicated by the 





The second restriction digest was performed using the restriction enzyme BamHI. Again, 
the same two colonies produced different products. This was observed in Figure 12 as seen by 





A third restriction digest was performed on the selected products using BamHI and Not1 
to confirm the results. The expected band sizes are as follows: the pCN42𝛥B template is ~ 1400 
bp and the FSHR-APEX template is ~ 2300 bp. The blue arrow in Figure 13 indicate the 
pCN42𝛥B template (FSHR template) and the yellow arrow indicates a slightly larger band 




Transient transfections of the FSHR-APEX plasmid were performed to use in a 
fluorescent microscopy experiment to demonstrate receptor presence at the cell surface of 
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HEK293 cells. Un-transfected HEK293 cells served as the negative control where no 
fluorescence was seen. The HEK293 cells stably expressing the wild-type FSHR served as the 
positive control where fluorescence is present. Fluorescent microscopy images of the transient 
transfections of the FSHR-APEX receptor indicate that the modified receptor was indeed present 




An FSH time course experiment was used to analyze receptor signaling (Figure 15). The 
modified plasmid was transiently transfected into HEK293 cells and FSH was added at 0, 5, and 
15 minutes. The cells were harvested and lysed and western blot analysis was used to probe for 
the downstream signaling product p44/42. Both FSHR-APEX-1 and FSHR-APEX-2, two 
separate transient transfections, produced p44/42 after FSH activation. However, the 






The FSHR-APEX plasmid was stably transfected into HEK293 cells. Individual colonies 
were grown until they were confluent in a 6-well plate. The cells were harvested and lysed to 
determine if the modified receptor was present. Western blot analysis indicated that 
FSHR-APEX clones 1, 2, and 3 in lanes 2, 3, and 4 are expressing the modified receptor (Figure 
16). The molecular weight of the wild-type FSHR is about 70kDa indicated by the green arrow 
in Figure 16 and the molecular weight of the APEX protein is around 27 kDa. Therefore, the 
FSHR-APEX receptor would be approximately 97kDa as indicated by the orange arrow in 



















Understanding the role of follicle stimulating hormone, follicle stimulating hormone 
receptor, and the downstream signaling pathways and effector proteins are crucial for explaining 
how the reproductive system functions and ultimately offering potential targets for fertility drugs 
and contraceptives. The APEX assay provides a method for studying the downstream pathways 
of GPCRs and was utilized to develop another option for studying FSHR signaling. To develop 
this assay, the APEX protein template was attached to the C-terminus of the FSHR template, 
allowing for effector proteins to be tagged in the cytoplasm.  
The fluorescent microscopy results indicate that the modified FSHR-APEX receptor is 
expressed on the cell surface of HEK293 cells. There is no fluorescence seen in the negative 
control and there is fluorescence seen in the wild-type FSHR, demonstrating that the 
fluorescence staining was successful. There is fluorescence seen from the FSHR-APEX receptor, 
indicating that the modified receptor is indeed expressed on the cell surface. However, the 
fluorescence is less than the wild-type FSHR. This is most likely due to a lower concentration of 
the plasmid transfected, resulting in the lower expression of the modified receptor.  
The FSH time course treatment was used to determine the modified receptor 
functionality. The downstream product p44/42 was probed for using western blot analysis. Both 
FSHR-APEX 1 and 2 produced the p44/42 product at 0, 5, and 15 minutes post FSH treatment. 
For both FSHR-APEX transient transfections 1 and 2, the highest p44/42 concentration was at 0 
minutes indicated by the darker bands in Figure 15, followed by the p44/42 concentration at 5 
minutes. The p44/42 concentration for FSHR-APEX-1 decreased between 5 minutes and 15 
minutes post FSH exposure, which is confirmed by the faint band seen at 15 minutes. The p44/42 
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concentration for FSHR-APEX-2 is seen to increase between 5 and 15 minutes after FSH 
exposure, indicated by the darker band at 15 minutes compared to 5 minutes in Figure 15. The 
inconsistencies between the two FSHR-APEX transfections could be from the use of a transient 
transfection. The amount of expression of the modified receptor could differ between the two 
resulting in different amounts of downstream products produced in the signaling cascade. The 
wild-type FSHR also shows p44/42 activation at all three time points. There is an increase in 
p44/42 concentration from 0 to 5 minutes and from 5 to 15 minutes after treatment with FSH. 
This is seen by the increasing darkness of the bands in Figure 15 for the wild-type receptor. 
However, at 0 minutes, it would be expected that no p44/42 expression would be seen. Thus, 
indicating that there were inconsistencies among the experimental design and execution. The 
un-transfected HEK293 cells also demonstrated a p44/42 response, which was unexpected. 
These cells do not express any isoform of the FSHR, and were used as the negative control 
where no response should have occured. Due to this, further analysis is needed to test the 
FSHR-APEX receptor signaling.  
The western blot analysis of the selection of colonies stably expressing the modified 
FSHR-APEX receptor showed that the receptor was in fact stably expressed in the HEK293 
cells, thus creating a new cell line. Three clones were selected for analysis where all three were 
found to express the modified receptor. The wild-type FSHR is seen at 70 kDa. Since the APEX 
protein is approximately 27 kDa, then the modified FSHR-APEX receptor is about 97 kDa, 
which is seen in the western blot. An FSHR specific antibody was also used, further emphasizing 
that the FSHR-APEX receptor is present. However, since clones 2 and 3 had a much higher 
expression of the modified receptor as indicated by the darker bands present in the western blot 
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The future experiments for this research include further analysis of the modified 
FSHR-APEX receptor functionality. This can be done using techniques like the EPAC assay to 
test for downstream cyclic AMP production after FSH activation as well as using western blot 
analysis to determine the p44/42 activation following treatment of FSH. The signaling of the 
FSHR-APEX receptor can be tested using the stable cell line expressing the modified receptor, 
which should decrease the amount of inconsistencies found when using a transient transfection. 
Once the signaling and functionality of the modified receptor is confirmed, the APEX Assay can 
be utilized to determine FSHR partners during receptor signaling. This assay allows for the 
determination of proteins in a close proximity to FSHR in a time dependent manner. To use the 
APEX Assay, cells expressing the FSHR-APEX receptor are incubated in biotin phenol. Next, 
FSH is added over a specific time course followed by the addition of hydrogen peroxide to 
initiate the assay. The reaction is then quenched with a quenching solution and the biotinylated 
proteins are isolated using a streptavidin pulldown. The biotinylated proteins can then be 
analyzed using gel electrophoresis, western blot analysis, and mass spectrometry to determine 
potential FSHR partners during signaling. This assay can help to identify potential targets for 














To conclude, the FSHR-APEX plasmid was created and successfully transfected into 
HEK293 cells, both transiently and stably. A new HEK293 cell line stably expressing the 
modified receptor was created for use in future experiments. This was confirmed by western blot 
analysis. Fluorescent microscopy results indicated that the modified receptor was indeed 
expressed on the cell surface of HEK293 cells. The functionality of the modified receptor was 
inconclusive and needs further testing.  
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